MedImmune’s data from a Phase III study showed that its next-generation investigational influenza vaccine, CAIV-T (cold adapted influenza vaccine, trivalent), was 55% more effective than the trivalent injectable inactivated influenza vaccine (TIV) in reducing influenza illness caused by any influenza strain in children six months to 59 months of age. The influenza attack rate was 8.6% for study participants receiving the flu shot compared to 3.9% for those who received CAIV-T (P <0.001)...